DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of treatments for neurological and kidney diseases. The company's lead product is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase II clinical trials for the treatment of acute ischemic stroke and kidney injury indications. It is also developing DM199 for the treatment vascular dementia. In addition, the company is developing DM300, which is in pre-clinical stage for the treatment for acute pancreatitis. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone763-496-5454
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable
DiaMedica Therapeutics (OTCMKTS:DMCAF) Frequently Asked Questions
What is DiaMedica Therapeutics' stock symbol?
DiaMedica Therapeutics trades on the OTCMKTS under the ticker symbol "DMCAF."
Has DiaMedica Therapeutics been receiving favorable news coverage?
Media coverage about DMCAF stock has trended somewhat positive recently, InfoTrie reports. The research firm identifies positive and negative press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. DiaMedica Therapeutics earned a media sentiment score of 1.7 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 4.0 out of 10, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next several days.
Who are some of DiaMedica Therapeutics' key competitors?
Some companies that are related to DiaMedica Therapeutics include Zafgen (ZFGN), Menlo Therapeutics (MNLO), REDHILL BIOPHAR/S (RDHL), ProMetic Life Sciences (PFSCF), Mersana Therapeutics (MRSN), AgeX Therapeutics (AGE), Ardelyx (ARDX), CytoDyn (CYDY), VBI Vaccines (VBIV), Spring Bank Pharmaceuticals (SBPH), Nature's Sunshine Products (NATR), Poxel (PXXLF), Syndax Pharmaceuticals (SNDX), Humanigen (HGEN) and BELLUS Health (BLUSF).
What other stocks do shareholders of DiaMedica Therapeutics own?
Who are DiaMedica Therapeutics' key executives?
DiaMedica Therapeutics' management team includes the folowing people:
- Mr. Rick Pauls MBA, CEO, Pres & Director (Age 47)
- Dr. Todd A. Verdoorn Ph.D., Chief Scientific Officer
- Mr. Scott B. Kellen, CFO & Company Sec. (Age 53)
- Mr. Edward B. Rady, Chief Commercial Advisor (Age 69)
- Dr. Dennis D. Kim M.D., MBA, Consulting Chief Medical Officer (Age 48)
How do I buy shares of DiaMedica Therapeutics?
Shares of DMCAF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How big of a company is DiaMedica Therapeutics?
DiaMedica Therapeutics has a market capitalization of $0.00.
What is DiaMedica Therapeutics' official website?
How can I contact DiaMedica Therapeutics?
DiaMedica Therapeutics' mailing address is 2 Carlson Parkway Suite 260, Minneapolis MN, 55447. The company can be reached via phone at 763-496-5454 or via email at [email protected]
MarketBeat Community Rating for DiaMedica Therapeutics (OTCMKTS DMCAF)
MarketBeat's community ratings are surveys of what our community members think about DiaMedica Therapeutics and other stocks. Vote "Outperform" if you believe DMCAF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DMCAF will underperform the S&P 500 over the long term. You may vote once every thirty days.
